Literature DB >> 27762194

Information technology concerning SDAI and CDAI.

Daniel Aletaha1, Manuel Bécède2, Josef S Smolen2.   

Abstract

Disease activity assessment of rheumatoid arthritis has never been trivial. Composite indices like the Disease Activity Score using 28 joint counts 28 (DAS28) and the Clinical Disease Activity Index (CDAI) and the Simplified Disease Activity Index (SDAI) attempted to integrate several core set variables into one readout, which eventually laid the grounds for implementation strategies that targeted disease activity levels, like remission. While CDAI and SDAI were clearly simpler at times when a calculator was needed, this has likely become less relevant in the era of digital records, where core set variables are entered into a computed device after measurement. However, DAS28 has faced new challenges, which are derived from its lack of specificity when it comes to assessing remission. Digital technology has advanced the management of patients with RA in clinical practice, since the disease activity levels can now be followed for each patient over adjustable time periods interesting for the clinician, such as since start of the last treatment. Also for research purposes, the digital records have allowed a more rapid course of projects from the scientific hypothesis to publication, simply by allowing to go to the digital database and select the items and observation needed. This has made clinical research much more efficient. In the digital era, the CDAI and SDAI can still be used on a piece of paper without the necessity of any electronic device, and it is exactly this flexibility and versatility of these two scores that account for their continued success.

Entities:  

Mesh:

Year:  2016        PMID: 27762194

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  4 in total

1.  Cytokines (IL-15, IL-21, and IFN-γ) in rheumatoid arthritis: association with positivity to autoantibodies (RF, anti-CCP, anti-MCV, and anti-PADI4) and clinical activity.

Authors:  Itzel Viridiana Reyes-Pérez; Pedro Ernesto Sánchez-Hernández; José Francisco Muñoz-Valle; Gloria Esther Martínez-Bonilla; Trinidad García-Iglesias; Verónica González-Díaz; Samuel García-Arellano; Sergio Cerpa-Cruz; Julissa Polanco-Cruz; María Guadalupe Ramírez-Dueñas
Journal:  Clin Rheumatol       Date:  2019-07-17       Impact factor: 2.980

2.  Extraction of Rheumatoid Arthritis Disease Activity Measures From Electronic Health Records Using Automated Processing Algorithms.

Authors:  Grant W Cannon; Jorge Rojas; Andreas Reimold; Ted R Mikuls; Debra Bergman; Brian C Sauer
Journal:  ACR Open Rheumatol       Date:  2019-10-30

3.  Presence of anti-acetylated peptide antibodies (AAPA) in inflammatory arthritis and other rheumatic diseases suggests discriminative diagnostic capacity towards early rheumatoid arthritis.

Authors:  Paul Studenic; Alessia Alunno; Daniela Sieghart; Holger Bang; Daniel Aletaha; Stephan Blüml; Helmuth Haslacher; Josef S Smolen; Roberto Gerli; Günter Steiner
Journal:  Ther Adv Musculoskelet Dis       Date:  2021-07-23       Impact factor: 5.346

4.  A systematic review of guidelines for managing rheumatoid arthritis.

Authors:  Aneela Mian; Fowzia Ibrahim; David L Scott
Journal:  BMC Rheumatol       Date:  2019-10-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.